2024 ASCO Annual Meeting The American Society of Clinical Oncology assumes no responsibility for errors or omissions in this publication. The reader is advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each drug to be administered to verify the dosage, the method and duration or administration, or contraindications.

It is the responsibility of the treating physician or other health care professional, relying on independent experience and knowledge of the patient, to determine drug, disease, and the best treatment for the patient

2024ASCOAnnualMeetingAbstracts

• GuidetoAbstracts
• PlenarySession…………………………………………………………………………………………………………………………………………………………. 1s
• SpecialClinicalScienceSymposia……………………………………………………………………………………………………………………………… 3s
• BreastCancer—Local/Regional/Adjuvant…………………………………………………………………………………………………………………… 6s
• BreastCancer—Metastatic………………………………………………………………………………………………………………………………………… 39s
• CareDelivery/ModelsofCare…………………………………………………………………………………………………………………………………….. 75s
• CentralNervousSystemTumors……………………………………………………………………………………………………………………………….. 112s
• DevelopmentalTherapeutics—Immunotherapy…………………………………………………………………………………………………………. 138s
• DevelopmentalTherapeutics—MolecularlyTargetedAgentsandTumorBiology………………………………………………………… 188s
• GastrointestinalCancer—ColorectalandAnal……………………………………………………………………………………………………………. 234s
• GastrointestinalCancer—Gastroesophageal,Pancreatic,andHepatobiliary………………………………………………………………… 270s
• GenitourinaryCancer—KidneyandBladder……………………………………………………………………………………………………………….. 323s
• GenitourinaryCancer—Prostate,Testicular,andPenile……………………………………………………………………………………………… 355s
• GynecologicCancer…………………………………………………………………………………………………………………………………………………… 388s
• HeadandNeckCancer……………………………………………………………………………………………………………………………………………….424s
• HematologicMalignancies—Leukemia,MyelodysplasticSyndromes,andAllotransplant…………………………………………….457s
• HematologicMalignancies—LymphomaandChronicLymphocyticLeukemia……………………………………………………………. 481s
• HematologicMalignancies—PlasmaCellDyscrasia…………………………………………………………………………………………………….506s
• LungCancer—Non–SmallCellLocal-Regional/SmallCell/OtherThoracicCancers……………………………………………………..524s
• LungCancer—Non–SmallCellMetastatic…………………………………………………………………………………………………………………. 557s
• MedicalEducationandProfessionalDevelopment………………………………………………………………………………………………………599s
• Melanoma/SkinCancers……………………………………………………………………………………………………………………………………………. 613s
• PediatricOncology…………………………………………………………………………………………………………………………………………………….642s
• Prevention,RiskReduction,andGenetics…………………………………………………………………………………………………………………..662s
• QualityCare/HealthServicesResearch……………………………………………………………………………………………………………………….692s
• Sarcoma……………………………………………………………………………………………………………………………………………………………………. 739s
• SymptomScienceandPalliativeCare…………………………………………………………………………………………………………………………762s

her link of guide

https://s3.amazonaws.com/files.oncologymeetings.org/prod/s3fs-public/2024-05/AM24-Abstracts.pdf

2024 ASCO Annual Meeting  American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

https://meetings.asco.org/meetings/2024-asco-annual-meeting/316/program-guide/scheduled-sessions

https://meetings.asco.org/meetings/2024-asco-annual-meeting/316/program-guide/my-agenda